Show newer
arawat

Down Syndrome Market Analysis & Forecast to 2030

DelveInsight's "Down Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Down Syndrome market report provides current treatment practices, emerging drugs, Down Syndrome market share of the individual therapies, current and forecasted Down Syndrome market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Down Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
For more details visit: delveinsight.com/report-store/

0
arawat

Atopic Dermatitis Market Analysis, Epidemiology and Market Forecast 2030

DelveInsight's "Atopic Dermatitis (AD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Report also covers current Atopic Dermatitis (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

For more details visit: delveinsight.com/report-store/

0
arawat

Dubai’s Pharmaceutical Market
According to estimates, Dubai’s pharma market is projected to grow by 9.6 per cent to USD 25.6 billion (AED 94 billion) by 2022, depicting a profitable opportunity to the pharma companies worldwide.
Dubai’s growing population, technological advancements and central geographical location are sure to lend a helping hand in increasing the value of the GCC and MEA pharmaceutical markets in the upcoming years.
Visit for more details: delveinsight.com/blog/dubai-a-

0
arawat

Stargardt Disease Market
Stargardt Disease prevalence is estimated to be 1 in 8,000 to 10,000 individuals.
Stargardt Disease is the most commonly inherited childhood and adulthood maculopathy and has Stargardt Disease prevalence of 1 in 10,000.
An annual Stargardt Disease incidence in the United Kingdom was between 0.110 and 0.128 per 100 000 individuals.

To read more visit: delveinsight.com/report-store/

0
arawat

Muscle Invasive Bladder cancer Market
Bladder cancer is the ninth most commonly diagnosed cancer worldwide, with more than 380,000 new cases each year and more than 150,000 deaths per year, and an estimated male-female ratio of 3.8:1.0.
In 2019, an estimated 80,470 adults (61,700 men and 18,770 women) in the United States had been diagnosed with bladder cancer.
Bladder cancer mostly affects older people. Ninety per cent (90%) of people with bladder cancer are older than 55, and the average age of people diagnosed with bladder cancer is around 73 years.

To read more visit: delveinsight.com/report-store/

0
arawat

Exocrine Pancreatic Insufficiency Market

The estimated Exocrine Pancreatic Insufficiency prevalence in Japan is more than 25 cases per 100,000 with a higher rate in men compared to women.
The estimated Exocrine Pancreatic Insufficiency prevalence in the defined German population is 6.4 cases per 100,000 inhabitants.
An apparent increase of disease with age is observed from 6.0% in the 50-54 years age group to 15.5% in the 65-69 years age group, and 13.4% in the 70-75 years age group.

To read more visit: delveinsight.com/report-store/

0
arawat

End-Stage Renal Disease Market
End-Stage Renal Disease is more common in men than in women. The prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) as compared to men (12.1%).
About 15% of adults in the US are estimated to have chronic kidney disease. Chronic kidney disease can often be treated before it progresses to end-stage renal failure or leads to other health problems.
End-Stage Renal Disease prevalence in the US in 2007 was 1,698 cases per million population. In 2007, Japan also observed relatively high prevalence, i.e., 2,060 cases per million population of End-Stage Renal Disease, which included only people receiving maintenance dialysis.
For more details visit: delveinsight.com/report-store/

0
arawat

Existing and Emerging healthcare Innovations
E-Health (Telehealth & Telemedicine), Wearable biosensors, Artificial intelligence (AI), Point-of-care testing, and Augmented Reality are some of the innovations that have significantly transformed the healthcare industry.
Drone-delivered medical supplies system, Internet of Things (IoT), stem-cell cure for diabetes, Precision Medicine, Regenerative medicine, a more diverse and accurate global biobank are some of the healthcare innovations and applications which are still in their infancy and initial research phases, if successfully capitalized, are expected to change the overall outlook of the healthcare system.

To Read More Visit: delveinsight.com/blog/top-heal

0
arawat

Soft Tissue Sarcoma Epidemiology
In the year 2017, the total Soft tissue sarcoma incident population in the 7MM was observed to be approximately 40,155. The US accounted for the maximum number of soft tissue sarcoma incidence cases, followed by Germany.
The Key Soft tissue sarcoma companies working in the field including Eli Lilly and Company, Novartis, GSK, Bayer Pharmaceuticals, Blueprint Medicines, Advenchen Laboratories, LLC /Jiangsu Chia-Tai Tianqing Pharmaceutical, Karyopharm Therapeutics Inc., Deciphera Pharmaceuticals, Philogen S.p.A., Epizyme, Pfizer, AADi Bioscience, INC, and many others are developing novel therapies to treat soft tissue sarcoma.
To read more visit: delveinsight.com/blog/soft-tis

0
arawat

Soft tissue sarcoma treatment market
Soft tissue sarcoma — a rare tumor — affecting less than 1% of the population — has the major unmet need in the form of limited treatment options for patients.
Cytotoxic chemotherapy has been the mainstay of for decades.
Pharma companies including Blueprint Medicines, Advenchen Laboratories, LLC/ Jiangsu Chia-Tai Tianqing Pharmaceutical, Karyopharm Therapeutics Inc., Deciphera Pharmaceuticals, Philogen S.p.A., GSK, Epizyme, Eli Lilly and Company, and several others are advancing the Soft Tissue Sarcoma Treatment market with novel therapies under trials in their pipeline, soon to be launched in the coming decade.
To read more visit: delveinsight.com/blog/soft-tis
 

0
arawat

Schizophrenia Market
Schizophrenia is a chronic and severe mental disorder, affects 20 million people globally.
Schizophrenia patients are 2-3 times more likely to die early than the general population.
The point Schizophrenia prevalence on adults ranges between 1 and 17 per 1000 population, one-year prevalence between 1 and 7.5 per 1000, and lifetime prevalence between 1 and 18 per 1000.
For more details visit: delveinsight.com/report-store/
Source: Delveinsight

0
arawat

Blastic Plasmacytoid Dendritic Cell Neoplasm Market
Blastic Plasmacytoid Dendritic Cell Neoplasm comprise of less than 1% of all hematologic malignancies, that results around 1,000 to 1,400 cases prevailing annually in the US and Europe when combined.

90% of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) patients with present asymptomatic skin lesions and early identification can be difficult due to overlapping features along with other benign and malignant disorders.

For more details Visit: delveinsight.com/report-store/
Source: Delveinsight

0
arawat

Gene therapy might make cocaine less addictive
According to the “National Survey on Drug Use and Health”, around 2.2 million Americans falling in the age group of 12 or older, were found to be actively using cocaine in the year 2017.
The last few years have witnessed a substantial investment in R&D aimed at finding effective Medication for cocaine addiction.
Gene therapy can be a potential and a novel approach to treat cocaine addiction and if it gets approved, it may dramatically change the outcome for millions of cocaine addicts worldwide.

Visit to read more: delveinsight.com/blog/gene-the
Source: Delveinsight

0
arawat

Opioid Withdrawal Syndrome Pipeline
The Opioid withdrawal syndrome market is going to leap forward attributed to the enhancement and strengthening of weak clinical Opioid withdrawal syndrome pipeline.
Key Pharma players such as Chiesi Farmaceutici, BioXcel Therapeutics, Aphios Pharmaceutical and others are going to advance the Opioid Withdrawal Syndrome therapy market further in future.
To read more on Opioid withdrawal syndrome pipeline visit:
delveinsight.com/blog/opioid-w

0
arawat

Complex Regional Pain Syndrome Epidemiology, Market Analysis, and Market Forecast
The Market Size of Complex Regional Pain Syndrome is expected to achieve USD 469.94 million by 2028 in 7 major markets.
The total cases of Complex Regional Pain Syndrome are expected to increase at a CAGR of 0.8% for the study period.
Among the 7 seven major markets, the united states account for the highest Complex Regional Pain Syndrome market, as compared to japan and EU5 countries.
Delveinsight Complex Regional Pain Syndrome market report comprises in-depth analysis of-
Descriptive overview and comprehensive insight of the Complex Regional Pain Syndrome epidemiology and market forecasts to 2028 in the 7 major markets (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.
Complex Regional Pain Syndrome market report provides details overview such as disease definition, causes, symptoms, risk factors, and pathophysiology and diagnostic trends.
The current and emerging therapies of Complex Regional Pain Syndrome.
The global historical and forecasted market of Complex Regional Pain Syndrome.
The Market report extensively covers some of the leading Complex Regional Pain Syndrome drugs such as Neridronate, BHV-5000, PPP001, AXS-02, and many others.
The Report methodically examines the Complex Regional Pain Syndrome drugs current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Visit for free sample pages of Complex Regional Pain Syndrome: delveinsight.com/sample-reques
On the basis of gender Complex, Regional Pain Syndrome is expected to affect females more frequently as compared to males. Similarly, on the basis of types, Complex Regional Pain Syndrome types II affects fewer number people as compared to Complex Regional Pain Syndrome type I".
Some of the Leading Companies in the Complex Regional Pain Syndrome Market includes Abiogen Pharma/Grünenthal, BioHeaven Pharmaceuticals, Tetra Bio-Pharma, Axsome Therapeutics and others.
In the coming years, the overall dynamics of the Complex Regional Pain Syndrome market is anticipated to change owing to the expected launch of emerging therapies, increasing patient pool, and many others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

0
arawat

Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast
During the year 2017 to 2028, the prevalent population of Cholangiocarcinoma (CCA) is expected to increase at a CAGR of 1.5%.
The United States recorded the highest incidence of Cholangiocarcinoma (CCA) in 2017.
Similarly, Germany accounted for the highest incident population of Cholangiocarcinoma (CCA) among the EU5 countries, followed by Italy and the UK.
Delveinsight Cholangiocarcinoma market report provides an in-depth overview of Cholangiocarcinoma historical and forecasted epidemiology in 7 major markets, covering EU5 (Germany, Spain, France, Italy and the United Kingdom), Japan, and the United States.
According to DelveInsight estimate, the incident population of Cholangiocarcinoma (CCA) was 18,729 in 7 major markets in 2018.
The Cholangiocarcinoma market report analyzes the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Cholangiocarcinoma (CCA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current diagnostic methods or tests for Cholangiocarcinoma, Competitive Intelligence Analysis of Cholangiocarcinoma, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Visit for free sample page: delveinsight.com/report-store/
Some of the key market players of the Cholangiocarcinoma market include Delcath Systems, Agios Pharmaceuticals, Basilea Pharmaceutica, Incyte Corporation, Bayer, and others.
Delveinsight Cholangiocarcinoma market report covers Cholangiocarcinoma (CCA) treatment algorithms and guidelines. The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. As of now some of the key drugs in the Cholangiocarcinoma market involve Infigratinib, Entrectinib, LOXO-101, Pemigatinib and others.
Cholangiocarcinoma (CCA) market is expected to change in the coming years. Rising awareness of Cholangiocarcinoma (CCA) market, incremental healthcare spending across the world, an increase in patient population are expected to expand the size of the Cholangiocarcinoma market in the coming years.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

0
arawat

Traveler's Diarrhea Treatment Market

Every year approximately around 10 million US citizens are affected by traveler’s diarrhea.
Among the EU5 countries, Germany had the highest percentage of diagnosed traveler’s diarrhea incident population in 2017 followed by italy.
Traveler diarrhea is a benign self illness lasting 3 to 5 day, the mean time period for traveler diarrhea is 3.6 days.
As pre DelveInsight, the incident population of Traveler's Diarrhea (TD) was estimated to be 41,611,405 in 7 major markets in 2018.
The United States accounts for the highest TD cases (16,964,730 in 2018), followed by EU5 (Germany, France, Italy, Spain and UK) and Japan.
Traveler's diarrhea (TD) is a digestive tract disorder accompanied by at least 1 of the following diseases and symptoms like fever, nausea, vomiting, cramps, tenesmus, or bloody stools (dysentery). It mainly occurs when a person travels from a developed nation to less developed or developing countries.
Traveler diarrhea is a benign self illness lasting 3 to 5 day, the mean time period for traveler diarrhea is 3.6 days.
Poor hygiene in developing countries is usually the main factor for Traveler's Diarrhea. Classic travelers' diarrhea is defined as at least three loose to watery stools in 24 hours with or without one or more symptoms of abdominal cramps, fever, nausea, vomiting, or blood in the stool. Mild to moderate diarrhea is one or two loose stools in 24 hours with or without another enteric symptom. The median time to onset is six or seven days after arrival. Although the diarrhea often resolves spontaneously over three or four days, up to a quarter of affected travelers need to alter their plans, interrupting their holiday or business activities.
DelveInsight's 'Traveler's Diarrhea Market report provides Traveler's Diarrhea Insights, Epidemiology and Market Forecast till 2028'. The report also delivers an in-depth understanding of the Traveler's Diarrhea in terms of market size, historical and forecasted epidemiology as well as the market trends in the EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and the United States,.
The key companies in Traveler's Diarrhea market includes:Procter and Gamble, Scandinavian Biopharma, Cosmo Pharmaceuticals, Salix Pharmaceuticals
Visit for Traveler's Diarrhea Sample Page: delveinsight.com/report-store/

Traveler's diarrhea Diagnosis and treatment
Marketed drugs for traveler's diarrhea include Aemcolo (rifamycin, Cosmo Pharmaceuticals), Xifaxan (rifaximin, Salix Pharmaceuticals).

Delveinsight’s Traveler's Diarrhea (TD) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Delveinsight’s Traveler's Diarrhea (TD) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Delveinsight’s Traveler's Diarrhea (TD) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits of Delveinsight’s Traveler's Diarrhea Report
The Delveinsight’s Traveler's Diarrhea Report will assist Business to develop their Strategies by understanding the Traveler's Diarrhea trends and forecasts that will shape and drive the Traveler's Diarrhea (TD) market in coming years. The report also provides Traveler's Diarrhea future market competition.

Visit for more information: delveinsight.com/report-store/

Source: Delveinsight

, , ,

0
arawat

Open-angle glaucoma treatment market

Open-angle glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by open-angle of the anterior iridocorneal chamber, typical optic nerve head changes, gradual loss of peripheral vision (characteristic visual field changes) followed by central visual field loss (blindness) for which intraocular pressure (IOP) is a significant risk factor.

Open-angle glaucoma is the commonest form of glaucoma and a significant cause of blindness. High intraocular pressure (IOP) is a considerable risk factor for the disease.

Open-angle glaucoma treatment aims to lower the IOP and thus reduce the risk of progressive loss of vision. IOP can be reduced by medications (eye drops), laser therapy, or surgery.

Open-angle glaucoma treatment should be initiated if signs of damage as a result of open-angle glaucoma are evident, such as disc haemorrhage, nerve fibre layer defects, asymmetric cupping, vertical ovalization or notching of the cup or if symptoms of elevated IOP are present (e.g., halos, blurred vision, pain, IOP consistently above 28 mmHg to 30 mmHg) due to the high risk of optic nerve damage. The targeted intraocular pressure should be achieved with the fewest medications and minimum adverse effects. Several different classes of pressure-lowering medicines are available, and medication choice may be influenced by cost, adverse effects, and dosing schedules.

In general, prostaglandin analogues (Latanoprost, travoprost, bimatoprost, etc.) are the first line of medical therapy. These are the active market holders in Glaucoma treatment market and major players for open-angle glaucoma. These drugs reduce intraocular pressure by reducing outflow resistance resulting in increased aqueous humour flow through the uveoscleral pathway. However, they are associated with local adverse effects, such as conjunctival hyperemia, elongation, and darkening of eyelashes, prostaglandin-associated periorbitopathy, and others. If there is an intolerance to the use of prostaglandin analogues, the second-line agents, such as β-Adrenergic blockers (Timolol, Betaxolol, etc.); α agonists (Apraclonidine, Brimonidine); Carbonic anhydrase inhibitors (Dorzolamide, Brinzolamide); cholinergic agonists (Pilocarpine) are used.

Although drugs, such as the β-adrenergic blockers and α-adrenergic agonists are active only during the day and not at night, as well as, some of these agents, such as β-adrenergic blockers, may also have significant systemic adverse effects. Moreover, combinatorial therapy of these medications can be used.

The FDA approval of new classes of nitric oxide-donating compounds, Vyzulta developed by Bausch & Lomb’s and Rho-kinase (ROCK) inhibitors, Rhopressa developed by Aerie Pharma, open up new possibilities in market and research. Rhopressa is the first entirely new class of glaucoma medication to be available since latanoprost was approved. It is FDA-approved treatment that lowers eye pressure in patients with open-angle glaucoma and ocular hypertension. Vyzulta is combinatorial therapy of Lomb/Nicox, making this the first drug to reduce stress while simultaneously dilating blood vessels to enhance blood flow in open-angle glaucoma patients.

Both medications occupied a decent share hold in the Glaucoma market. If the first- and second-line treatment does not achieve adequate intraocular pressure, reduction with acceptable adverse effects, laser or incisional surgeries are indicated. In poorly adherent patients or those with severe disease, surgery may sometimes be offered as first-line therapy.

Despite all these available treatments, unfortunately, no competent evidence exists that these agents can prevent disease progression in patients with open-angle glaucoma, which is the major impediment in Open-angle glaucoma market growth. In part, neuroprotection has not succeeded because of an incomplete understanding of the pathophysiological mechanisms associated with optic nerve damage. The detailed knowledge of pathophysiology may change and drive the Open-angle glaucoma treatment market in the future. The frequent research has been directed toward understanding the disease at the cellular, hormonal, and molecular levels in order to overcome the current unmet needs.

The future holds the hope of developing drugs that target the autoregulatory function of the capillaries serving the optic nerve head with the expectation that better vascular perfusion will help retard the morbidity of the disease. Moreover, acquisitions and collaborations between key players, research and development, along with the emerging pipeline drugs, are expected to create a productive environment, as well as the launches of upcoming therapies will also provide to the overall growth of Open-angle glaucoma market during the forecast period of 2019–2028.

For more details visit : delveinsight.com/report-store/
Source: Delveinsight

0
arawat

How is Small Cell Lung Cancer Market changing future trends?

Lung cancer mainly begins in the lungs, and it may extend to lymph nodes or other body organs like the brain. However, cancer from other organs may also spread to the lungs. Cancer cells are known as metastases when cancer cells spread from one organ to another. There are chiefly two types of lung cancer SCLC and non-small cell lung cancer (NSCLC, the more common).

Small cell lung cancer (SCLC) is fast-growing lung cancer. It usually starts in bronchi (centre of the chest). Though the cancer cells are small, they increase aggressively and create large tumors. This kind of tumors often metastasizes quickly to other parts of the body. SCLC has two stages, such as; limited-stage and extensive-stage. The primary goal of staging in SCLC is to determine whether cancer has spread or not.

Small cell lung cancer market size in the 7MM countries is expected to increase by 2030 from USD 444 million in 2017. As per DelveInsight’s estimation, the market size of First-line extensive SCLC is likely to rise by 2030, from USD 243 million in 2017 during the study period (2017–2030).

As SCLC is such a weak prognostic cause of death worldwide, it attracts much attention from the pharmaceutical industry, which has resulted in an active SCLC pipeline. There are giant pharmaceutical companies like AstraZeneca, PharmaMar, EpicentRx, G1 Therapeutics, and several others that are involved in developing SCLC drugs.

The available therapeutics treatment options in Small Cell Lung Cancer Landscape aim to reduce complications arising from blood accumulating in joint spaces and other tissues and organs.

The dynamics of the SCLC market will change in the coming years due to the improvement in the rise in healthcare services spending across the world. The drugs are Infinzi of AstraZeneca, Trilaciclib of G1 Therapeutics, Lurbinectedin; Zepsyre, PM1183 of PharmaMar, and RRx-001 of EpicentRx and many others.

The positive results of investigational products and a robust SCLC pipeline bring a ray of hope for a better Small cell lung cancer treatment pattern in the market in the coming years. The current scenario also anticipates a positive shift in the Small cell lung cancer market for a study period (2017–2030).

For more details visit : delveinsight.com/report-store/
Source: Delveinsight

0
arawat

Opioid Withdrawal Syndrome
Patients and people grappling opioids, whether as medicine, after giving up their use, suffer from withdrawal symptoms such fatigue, nausea, pain, and this condition is known as Opioid withdrawal syndrome (OWS). The symptoms of Opioid withdrawal syndrome may vary with the dependence of a person on opioids.
As per the survey by National Survey on Drug Use and Health, around 5.2 million Americans (which is 2.1% of total US population) used prescription opioids non-medically in the past month revealing similar results. Several Pharma companies such as Chiesi Farmaceutici, Aphios Corporation, and US WorldMeds are working to tackle the current unmet need in an opioid withdrawal syndrome.
Some of the emerging therapies for the Opioid withdrawal syndrome treatment include CHF6563 (Chiesi Farmaceutici), APH-1501 (Aphios Corporation), Lofexidine (US WorldMeds), and several others.
For more details visit delveinsight.com/blog/opioid-w or refer to delveinsight.com/

0
Show older
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.

Trending now

Resources

Developers

What is Mastodon?

qoto.org

More…

v3.5.19-qoto · Privacy policy